This HTML5 document contains 142 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00231/identifier/pubchem-compound/
n23http://linked.opendata.cz/resource/AHFS/
n6http://linked.opendata.cz/resource/mesh/concept/
n12http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00231/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00231/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00231/identifier/drugbank/
n29http://www.drugs.com/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00231/identifier/national-drug-code-directory/
n19http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00231/identifier/chemspider/
n4http://www.rxlist.com/cgi/generic/
n27http://linked.opendata.cz/resource/drugbank/patent/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/mesh/
n8http://linked.opendata.cz/resource/drugbank/property/
n24http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00231/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00231/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00231
rdf:type
n7:Drug
n7:description
A benzodiazepine that acts as a gamma-aminobutyric acid modulator and anti-anxiety agent. [PubChem]
n7:dosage
n20:271B61A8-363D-11E5-9242-09173F13E4C5 n20:271B61A9-363D-11E5-9242-09173F13E4C5 n20:271B61AA-363D-11E5-9242-09173F13E4C5 n20:271B61AB-363D-11E5-9242-09173F13E4C5
n7:generalReferences
# Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2883820 # Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2570451 # Vozeh S: [Pharmacokinetic of benzodiazepines in old age] Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6118950 # Shats V, Kozacov S: [Falls in the geriatric department: responsibility of the care-giver and the hospital] Harefuah. 1995 Jun 1;128(11):690-3, 743. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7557666 # Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18375
n7:group
approved
n7:halfLife
10-20 hours
n7:indication
For the short-term treatment of insomnia (generally 7-10 days).
n7:manufacturer
n12:271B6195-363D-11E5-9242-09173F13E4C5 n12:271B6193-363D-11E5-9242-09173F13E4C5 n12:271B6194-363D-11E5-9242-09173F13E4C5 n12:271B6191-363D-11E5-9242-09173F13E4C5 n12:271B6192-363D-11E5-9242-09173F13E4C5 n12:271B618F-363D-11E5-9242-09173F13E4C5 n12:271B6190-363D-11E5-9242-09173F13E4C5 n12:271B618D-363D-11E5-9242-09173F13E4C5 n12:271B618E-363D-11E5-9242-09173F13E4C5 n12:271B618C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00231 n22:DB00231
dcterms:title
Temazepam
adms:identifier
n10:Temazepam n11:5391 n13:46506604 n14:53489-648-07 n15:PA451608 n25:D00370 n26:5198 n28:DB00231
n7:mechanismOfAction
Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
n7:packager
n12:271B6181-363D-11E5-9242-09173F13E4C5 n12:271B6182-363D-11E5-9242-09173F13E4C5 n12:271B617F-363D-11E5-9242-09173F13E4C5 n12:271B6180-363D-11E5-9242-09173F13E4C5 n12:271B6185-363D-11E5-9242-09173F13E4C5 n12:271B6186-363D-11E5-9242-09173F13E4C5 n12:271B6183-363D-11E5-9242-09173F13E4C5 n12:271B6184-363D-11E5-9242-09173F13E4C5 n12:271B6189-363D-11E5-9242-09173F13E4C5 n12:271B618A-363D-11E5-9242-09173F13E4C5 n12:271B6187-363D-11E5-9242-09173F13E4C5 n12:271B6188-363D-11E5-9242-09173F13E4C5 n12:271B618B-363D-11E5-9242-09173F13E4C5 n12:271B6161-363D-11E5-9242-09173F13E4C5 n12:271B6162-363D-11E5-9242-09173F13E4C5 n12:271B615F-363D-11E5-9242-09173F13E4C5 n12:271B6160-363D-11E5-9242-09173F13E4C5 n12:271B6165-363D-11E5-9242-09173F13E4C5 n12:271B6166-363D-11E5-9242-09173F13E4C5 n12:271B6163-363D-11E5-9242-09173F13E4C5 n12:271B6164-363D-11E5-9242-09173F13E4C5 n12:271B6169-363D-11E5-9242-09173F13E4C5 n12:271B616A-363D-11E5-9242-09173F13E4C5 n12:271B6167-363D-11E5-9242-09173F13E4C5 n12:271B6168-363D-11E5-9242-09173F13E4C5 n12:271B616D-363D-11E5-9242-09173F13E4C5 n12:271B616E-363D-11E5-9242-09173F13E4C5 n12:271B616B-363D-11E5-9242-09173F13E4C5 n12:271B616C-363D-11E5-9242-09173F13E4C5 n12:271B6171-363D-11E5-9242-09173F13E4C5 n12:271B6172-363D-11E5-9242-09173F13E4C5 n12:271B616F-363D-11E5-9242-09173F13E4C5 n12:271B6170-363D-11E5-9242-09173F13E4C5 n12:271B6175-363D-11E5-9242-09173F13E4C5 n12:271B6176-363D-11E5-9242-09173F13E4C5 n12:271B6173-363D-11E5-9242-09173F13E4C5 n12:271B6174-363D-11E5-9242-09173F13E4C5 n12:271B6179-363D-11E5-9242-09173F13E4C5 n12:271B617A-363D-11E5-9242-09173F13E4C5 n12:271B6177-363D-11E5-9242-09173F13E4C5 n12:271B6178-363D-11E5-9242-09173F13E4C5 n12:271B617D-363D-11E5-9242-09173F13E4C5 n12:271B617E-363D-11E5-9242-09173F13E4C5 n12:271B617B-363D-11E5-9242-09173F13E4C5 n12:271B617C-363D-11E5-9242-09173F13E4C5 n12:271B615E-363D-11E5-9242-09173F13E4C5
n7:patent
n27:5211954
n7:routeOfElimination
Temazepam was completely metabolized through conjugation prior to excretion; 80% to 90% of the dose appeared in the urine.
n7:synonym
Restoril
n16:hasAHFSCode
n23:28-24-08
n7:foodInteraction
Avoid avocado. Avoid alcohol. Avoid excessive quantities of coffee or tea (Caffeine).
n7:proteinBinding
96%
n5:hasConcept
n6:M0021137
foaf:page
n4:temaz.htm n24:res1373.shtml n29:temazepam.html
n7:IUPAC-Name
n8:271B61B0-363D-11E5-9242-09173F13E4C5
n7:InChI
n8:271B61B6-363D-11E5-9242-09173F13E4C5
n7:Molecular-Formula
n8:271B61B5-363D-11E5-9242-09173F13E4C5
n7:Molecular-Weight
n8:271B61B2-363D-11E5-9242-09173F13E4C5
n7:Monoisotopic-Weight
n8:271B61B3-363D-11E5-9242-09173F13E4C5
n7:SMILES
n8:271B61B4-363D-11E5-9242-09173F13E4C5
n7:Water-Solubility
n8:271B61C6-363D-11E5-9242-09173F13E4C5 n8:271B61AE-363D-11E5-9242-09173F13E4C5
n7:logP
n8:271B61C8-363D-11E5-9242-09173F13E4C5 n8:271B61AC-363D-11E5-9242-09173F13E4C5 n8:271B61AF-363D-11E5-9242-09173F13E4C5
n7:logS
n8:271B61AD-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:N05CD07
n7:H-Bond-Acceptor-Count
n8:271B61BC-363D-11E5-9242-09173F13E4C5
n7:H-Bond-Donor-Count
n8:271B61BD-363D-11E5-9242-09173F13E4C5
n7:InChIKey
n8:271B61B7-363D-11E5-9242-09173F13E4C5
n7:Polar-Surface-Area--PSA-
n8:271B61B8-363D-11E5-9242-09173F13E4C5
n7:Polarizability
n8:271B61BA-363D-11E5-9242-09173F13E4C5
n7:Refractivity
n8:271B61B9-363D-11E5-9242-09173F13E4C5
n7:Rotatable-Bond-Count
n8:271B61BB-363D-11E5-9242-09173F13E4C5
n7:absorption
Well absorbed, minimal first-pass metabolism.
n7:affectedOrganism
Humans and other mammals
n7:casRegistryNumber
846-50-4
n7:category
n7:containedIn
n21:271B6198-363D-11E5-9242-09173F13E4C5 n21:271B6199-363D-11E5-9242-09173F13E4C5 n21:271B6196-363D-11E5-9242-09173F13E4C5 n21:271B6197-363D-11E5-9242-09173F13E4C5 n21:271B619C-363D-11E5-9242-09173F13E4C5 n21:271B619D-363D-11E5-9242-09173F13E4C5 n21:271B619A-363D-11E5-9242-09173F13E4C5 n21:271B619B-363D-11E5-9242-09173F13E4C5 n21:271B61A0-363D-11E5-9242-09173F13E4C5 n21:271B61A1-363D-11E5-9242-09173F13E4C5 n21:271B619E-363D-11E5-9242-09173F13E4C5 n21:271B619F-363D-11E5-9242-09173F13E4C5 n21:271B61A4-363D-11E5-9242-09173F13E4C5 n21:271B61A5-363D-11E5-9242-09173F13E4C5 n21:271B61A2-363D-11E5-9242-09173F13E4C5 n21:271B61A3-363D-11E5-9242-09173F13E4C5 n21:271B61A6-363D-11E5-9242-09173F13E4C5 n21:271B61A7-363D-11E5-9242-09173F13E4C5
n7:Bioavailability
n8:271B61C2-363D-11E5-9242-09173F13E4C5
n7:Ghose-Filter
n8:271B61C4-363D-11E5-9242-09173F13E4C5
n7:MDDR-Like-Rule
n8:271B61C5-363D-11E5-9242-09173F13E4C5
n7:Melting-Point
n8:271B61C7-363D-11E5-9242-09173F13E4C5
n7:Number-of-Rings
n8:271B61C1-363D-11E5-9242-09173F13E4C5
n7:Physiological-Charge
n8:271B61C0-363D-11E5-9242-09173F13E4C5
n7:Rule-of-Five
n8:271B61C3-363D-11E5-9242-09173F13E4C5
n7:Traditional-IUPAC-Name
n8:271B61B1-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-acidic-
n8:271B61BE-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-basic-
n8:271B61BF-363D-11E5-9242-09173F13E4C5